Yifan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yifan Wang has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Chengguo Xing
Department of Medicinal Chemistry, Center for Natural Products, Drug Discovery and Development (CNPD3), College of Pharmacy, University of Florida, Gainesville, Florida 32610, United States
4 shared publications Leah R. Reznikov
Department of Physiological Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida 32610, United States
3 shared publications- Adriaan W. Bruijnzeel
Department of Psychiatry, University of Florida, Gainesville, FL, USA
2 shared publications Tara Hashemian
2 shared publicationsTengfei Bian
Department of Medicinal Chemistry and Center for Natural Products, Drug Discovery, and Development, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
2 shared publicationsTuo Lin
2 shared publications
Latest Publications
- 10 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Feasibility and safety of a 4-week AB-free kava intervention among adults who smoke cigarettes and its effects on reducing lung cancer risk biomarkers: a pilot trial
Because of the high prevalence of lung cancer, its poor clinical prognosis, and cigarette smoke being the dominant cause, preventive agents are urgently needed to help reduce lung cancer risk among those with tobacco exposure. Motivated by epidemiological observation, pre-clinical data, and pilot single-arm trial results, AB-free kava (a kava formular of consistent kavalactone composition and free of potentially hepatotoxic flavokavains A and B) may safely prevent cigarette smoke-induced lung cancer. The objective of this study was to evaluate a 4-week AB-free kava intervention among adult smokers for its feasibility, safety, and effects on lung cancer risk biomarkers (urinary 3-methyladenine (3-mA), total nicotine equivalent (TNE)-corrected 3-mA, and plasma 1-(3-pyridyl)-1,4-butanediol (PBD)) via a pilot randomized double-blind placebo-controlled trial. Data were collected during (Week 0, 1, 2, and 4) and after (Week 8 and 12) AB-free kava intervention with nineteen eligible participants enrolled and analyzed (10 in the placebo arm and 9 in the AB-free kava arm). Two participants in the placebo arm experienced liver enzyme elevations, with no elevation observed in the AB-free kava arm. More adverse events (self-addressed) were observed in the placebo arm than in the AB-free kava arm. AB-free kava intervention significantly reduced TNE-corrected 3-mA and showed the trends to reduce urinary 3-mA and plasma PBD. The trial results thus support the feasibility and safety of the 4-week AB-free kava intervention among adults who smoke and preliminarily reveal its efficacy in reducing lung cancer risk, which requires further validation.
- 10 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Feasibility and safety of a 4-week AB-free kava intervention among adults who smoke cigarettes and its effects on reducing lung cancer risk biomarkers: a pilot trial
Because of the high prevalence of lung cancer, its poor clinical prognosis, and cigarette smoke being the dominant cause, preventive agents are urgently needed to help reduce lung cancer risk among those with tobacco exposure. Motivated by epidemiological observation, pre-clinical data, and pilot single-arm trial results, AB-free kava (a kava formular of consistent kavalactone composition and free of potentially hepatotoxic flavokavains A and B) may safely prevent cigarette smoke-induced lung cancer. The objective of this study was to evaluate a 4-week AB-free kava intervention among adult smokers for its feasibility, safety, and effects on lung cancer risk biomarkers (urinary 3-methyladenine (3-mA), total nicotine equivalent (TNE)-corrected 3-mA, and plasma 1-(3-pyridyl)-1,4-butanediol (PBD)) via a pilot randomized double-blind placebo-controlled trial. Data were collected during (Week 0, 1, 2, and 4) and after (Week 8 and 12) AB-free kava intervention with nineteen eligible participants enrolled and analyzed (10 in the placebo arm and 9 in the AB-free kava arm). Two participants in the placebo arm experienced liver enzyme elevations, with no elevation observed in the AB-free kava arm. More adverse events (self-addressed) were observed in the placebo arm than in the AB-free kava arm. AB-free kava intervention significantly reduced TNE-corrected 3-mA and showed the trends to reduce urinary 3-mA and plasma PBD. The trial results thus support the feasibility and safety of the 4-week AB-free kava intervention among adults who smoke and preliminarily reveal its efficacy in reducing lung cancer risk, which requires further validation.
- Open Access
AB-Free Kava and its Kavalactones Suppress Cigarette Smoke- and Lipopolysaccharide-Induced Lung Inflammation: Efficacy and Mechanisms
Cigarette smoke-induced lung inflammation is a central driver of pulmonary diseases. The limited efficacy of current anti-inflammatory agents underscores the need for structurally novel therapeutics with distinct mechanisms. We recently demonstrated that AB-free kava, a flavokavains A/B-depleted formulation from Piper methysticum containing six major kavalactones, effectively suppresses cigarette smoke–induced lung inflammation in mice. This study aims to identify the bioactive constituent(s) and elucidate underlying mechanisms. These kavalactones revealed a clear structure–activity relationship in suppressing lipopolysaccharide (LPS)-stimulated prostaglandin E₂ (PGE₂) production in macrophages with desmethoxyyangonin (DMY) as the most potent kavalactone whereas dihydrokavain (DHK, a structurally similar analog) with minimal activity. DMY also effectively reduced LPS-induced interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) production while DHK was ineffective. Mechanistically, DMY, but not DHK, attenuated COX-2 induction and reduced phosphorylation of cAMP response element–binding protein (CREB). Pharmacological inhibition of protein kinase A (PKA) similarly reduced p-CREB, COX-2 and PGE 2 , supporting a PKA-dependent CREB/COX-2 signaling in mediating PGE₂ suppression while these effects were independent of nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) signaling. Similar results were observed for DMY and DHK in attenuating cigarette smoke condensate-induced proinflammatory pathways and PGE 2 production. Consistently, DMY demonstrated significant in vivo efficacy in suppressing cigarette smoke– induced lung inflammation while DHK was not effective. Interestingly, dihydromethysticin (DHM) demonstrated the greatest in vivo anti-inflammatory efficacy, although it only exhibited moderate in vitro potency, likely due to its superior bioavailability over DMY. Concordantly, cigarette smoke exposure elevated p-CREB and COX-2 expressions in mouse lungs, which were attenuated by AB-free kava and its bioactive kavalactones with the extent of suppression correlating with their in vivo anti-inflammatory efficacy. DHM effectively suppressed LPS-induced neutrophil accumulation in mouse lungs as well. Collectively, these studies identify bioactive kavalactones in AB-free kava that suppress cigarette smoke- and LPS-induced lung inflammation through the modulation of the PKA/CREB/COX-2 signaling axis, providing a foundation for developing structurally distinct anti-inflammatory agents, particularly targeting smoke-induced inflammation and associated pulmonary diseases. Graphic
Open AccessAB-Free Kava and its Kavalactones Suppress Cigarette Smoke- and Lipopolysaccharide-Induced Lung Inflammation: Efficacy and Mechanisms
Cigarette smoke-induced lung inflammation is a central driver of pulmonary diseases. The limited efficacy of current anti-inflammatory agents underscores the need for structurally novel therapeutics with distinct mechanisms. We recently demonstrated that AB-free kava, a flavokavains A/B-depleted formulation from Piper methysticum containing six major kavalactones, effectively suppresses cigarette smoke–induced lung inflammation in mice. This study aims to identify the bioactive constituent(s) and elucidate underlying mechanisms. These kavalactones revealed a clear structure–activity relationship in suppressing lipopolysaccharide (LPS)-stimulated prostaglandin E₂ (PGE₂) production in macrophages with desmethoxyyangonin (DMY) as the most potent kavalactone whereas dihydrokavain (DHK, a structurally similar analog) with minimal activity. DMY also effectively reduced LPS-induced interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) production while DHK was ineffective. Mechanistically, DMY, but not DHK, attenuated COX-2 induction and reduced phosphorylation of cAMP response element–binding protein (CREB). Pharmacological inhibition of protein kinase A (PKA) similarly reduced p-CREB, COX-2 and PGE 2 , supporting a PKA-dependent CREB/COX-2 signaling in mediating PGE₂ suppression while these effects were independent of nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1) signaling. Similar results were observed for DMY and DHK in attenuating cigarette smoke condensate-induced proinflammatory pathways and PGE 2 production. Consistently, DMY demonstrated significant in vivo efficacy in suppressing cigarette smoke– induced lung inflammation while DHK was not effective. Interestingly, dihydromethysticin (DHM) demonstrated the greatest in vivo anti-inflammatory efficacy, although it only exhibited moderate in vitro potency, likely due to its superior bioavailability over DMY. Concordantly, cigarette smoke exposure elevated p-CREB and COX-2 expressions in mouse lungs, which were attenuated by AB-free kava and its bioactive kavalactones with the extent of suppression correlating with their in vivo anti-inflammatory efficacy. DHM effectively suppressed LPS-induced neutrophil accumulation in mouse lungs as well. Collectively, these studies identify bioactive kavalactones in AB-free kava that suppress cigarette smoke- and LPS-induced lung inflammation through the modulation of the PKA/CREB/COX-2 signaling axis, providing a foundation for developing structurally distinct anti-inflammatory agents, particularly targeting smoke-induced inflammation and associated pulmonary diseases. Graphic
- Open Access
- 6 December 2025
- Published by Elsevier in Phytomedicine Plus
- Vol. 6 (1)
AB-free kava suppresses tobacco smoke-induced CREB phosphorylation in the mouse cerebellum
- 6 December 2025
- Published by Elsevier in Phytomedicine Plus
- Vol. 6 (1)
Open AccessAB-free kava suppresses tobacco smoke-induced CREB phosphorylation in the mouse cerebellum
- Open Access
AB-Free Kava Suppresses Tobacco Smoke-Induced CREB Phosphorylation in the Mouse Cerebellum
Introduction: Our recent studies revealed the potential of AB-free kava as a novel therapeutic candidate against tobacco use disorder while the underlying mechanism remains to be elucidated. The cerebellum region in the brain has recently been reported to be involved in tobacco smoke withdrawal. The cAMP response element-binding protein (CREB) activation via phosphorylation has also been reported to contribute to substance abuse, including tobacco use disorder. Our early pre-clinical work revealed the potential of AB-free kava to suppress tobacco smoke-induced CREB activation in lung tissues. Methods: In this study, we investigated the impact of tobacco smoke exposure on the levels of phosphorylated CREB (p-CREB) in the mouse cerebellum and evaluated the effects of AB-free kava. Results: Four different regimens of tobacco smoke exposure consistently increased the levels of p-CREB in the cerebellum. Importantly, AB-free kava effectively suppressed tobacco smoke-induced increase in p-CREB to levels comparable to mice without tobacco smoke exposure. Conclusions: CREB activation in the cerebellum is a potential mechanism involved in tobacco use disorder, and our data provide preliminary evidence for the protective potential of AB-free kava.
Open AccessAB-Free Kava Suppresses Tobacco Smoke-Induced CREB Phosphorylation in the Mouse Cerebellum
Introduction: Our recent studies revealed the potential of AB-free kava as a novel therapeutic candidate against tobacco use disorder while the underlying mechanism remains to be elucidated. The cerebellum region in the brain has recently been reported to be involved in tobacco smoke withdrawal. The cAMP response element-binding protein (CREB) activation via phosphorylation has also been reported to contribute to substance abuse, including tobacco use disorder. Our early pre-clinical work revealed the potential of AB-free kava to suppress tobacco smoke-induced CREB activation in lung tissues. Methods: In this study, we investigated the impact of tobacco smoke exposure on the levels of phosphorylated CREB (p-CREB) in the mouse cerebellum and evaluated the effects of AB-free kava. Results: Four different regimens of tobacco smoke exposure consistently increased the levels of p-CREB in the cerebellum. Importantly, AB-free kava effectively suppressed tobacco smoke-induced increase in p-CREB to levels comparable to mice without tobacco smoke exposure. Conclusions: CREB activation in the cerebellum is a potential mechanism involved in tobacco use disorder, and our data provide preliminary evidence for the protective potential of AB-free kava.
- 4 February 2023
- Published by Elsevier in Phytomedicine
- Vol. 112, 154701
Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe2+ accumulation
- 4 February 2023
- Published by Elsevier in Phytomedicine
- Vol. 112, 154701
Shikonin and cisplatin synergistically overcome cisplatin resistance of ovarian cancer by inducing ferroptosis via upregulation of HMOX1 to promote Fe2+ accumulation
- 13 September 2022
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 70 (38) , 12128-12134
Boosting the Heterologous Expression of d-Allulose 3-Epimerase in Bacillus subtilis through Protein Engineering and Catabolite-Responsive Element Box Engineering
As a natural sweetener with low calories and various physiological activities, d-allulose has drawn worldwide attention. Currently, d-allulose 3-epimerase (DAEase) is mainly used to catalyze the epimerization of d-fructose to d-allulose. Therefore, it is quite necessary to enhance the food-grade expression of DAEase to meet the surging market demand for d-allulose. In this study, initially, the promising variant H207L/D281G/C289R of Clostridium cellulolyticum H10 DAEase (CcDAEase) was generated by protein engineering, the specific activity and the T1/2 of which were 2.24-fold and 13.45-fold those of the CcDAEase wild type at 60 °C, respectively. After that, PamyE was determined as the optimal promoter for the recombinant expression of CcDAEase in Bacillus subtilis, and catabolite-responsive element (CRE) box engineering was further performed to eliminate the carbon catabolite repression (CCR) effect. Lastly, high-density fermentation was carried out and the final activity peaked at 4971.5 U mL-1, which is the highest expression level and could effectively promote the industrial production of DAEase. This research provides a theoretical basis and technical support for the molecular modification of DAEase and its efficient fermentation preparation.
- 13 September 2022
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 70 (38) , 12128-12134
Boosting the Heterologous Expression of d-Allulose 3-Epimerase in Bacillus subtilis through Protein Engineering and Catabolite-Responsive Element Box Engineering
As a natural sweetener with low calories and various physiological activities, d-allulose has drawn worldwide attention. Currently, d-allulose 3-epimerase (DAEase) is mainly used to catalyze the epimerization of d-fructose to d-allulose. Therefore, it is quite necessary to enhance the food-grade expression of DAEase to meet the surging market demand for d-allulose. In this study, initially, the promising variant H207L/D281G/C289R of Clostridium cellulolyticum H10 DAEase (CcDAEase) was generated by protein engineering, the specific activity and the T1/2 of which were 2.24-fold and 13.45-fold those of the CcDAEase wild type at 60 °C, respectively. After that, PamyE was determined as the optimal promoter for the recombinant expression of CcDAEase in Bacillus subtilis, and catabolite-responsive element (CRE) box engineering was further performed to eliminate the carbon catabolite repression (CCR) effect. Lastly, high-density fermentation was carried out and the final activity peaked at 4971.5 U mL-1, which is the highest expression level and could effectively promote the industrial production of DAEase. This research provides a theoretical basis and technical support for the molecular modification of DAEase and its efficient fermentation preparation.